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Introduction 
Prostate biopsy presents a significant percentage of complications. Infection complicates 
more than 5% of patients subjected to prostate biopsy1 and is the most common reason for 
hospitalization following prostate biopsy2,3. The factors predicting a higher susceptibility to 
infection have been largely unknown but some literature have highlighted in the 
aetiopathogenesis the importance of augmented prevalence of ciprofloxacin resistant 
bacterial strains (E. coli) in the rectum flora.  
Case report 
We report a case of an elderly man, who had no urinary symptoms. A 74year old man presented 
in our general outpatient clinic with no urinary symptom but had elevated total serum Prostate 
Specific Antigen (PSA) during his annual medical check-up. The PSA was 19.01ng/ml, which 
prompted the attending physician to refer him to our Urology Clinic.  
We found him to be a healthy-looking elderly man. The findings on general examination were 
essentially normal. On digital rectal examination, the sphincteric tone was normal; the rectal 
mucosa was smooth; the prostate gland was enlarged, grade III, smooth, firm, nontender, 
median groove and lateral sulci were preserved. We made a clinical diagnosis of chronic 
prostatitis.  
 
A repeat serum PSA test was 17.90ng/ml. The ultrasonography revealed a 79.7gm homogenous 
prostate gland. He was commenced on oral ciprofloxacine 500mg twice daily for six weeks, 
based on the presumptive diagnosis of chronic prostatitis. Thereafter the serum PSA was 
24.60ng/ml.  He was consequently scheduled for a transrectal prostate biopsy. Pre-biopsy, IV 
pentazocine 15mg, IV acetaminophen 600mg and IV Gentamycin 160mg were given. He had 
caudal block anaesthesia with 200mg plain lidocaine and an extended (10 cores) biopsy was 
performed. After the biopsy, he was commenced on oral ciprofloxacine 500mg twice daily for 
five days and acetaminophen 1000mg three times daily for three days. 
 
Four days after the prostate biopsy, he developed severe weakness, fever (37.2oC) and 
haematuria, suggestive of septicaemia. Urine culture did not yield any organism. He was treated 
with intravenous ceftriazone and Gentamycin, there was resolution of his symptoms and he was 
discharged after eight days of admission. However he re-presented four days later with severe 
weakness and fever (38.3oC). The urine culture yielded no growth of organism. Preliminary 
blood culture yielded Streptococcus species. He was treated with intravenous levofloxacine. 
At this point, the histology report was available, showing fibromuscular hypertrophy with 
glandular hyperplasia and chronic inflammation. 
 
He developed hypotension( BP 80/50mmHg); packed cell volume = 19%; white cell count = 
44.3 x 109/L. On peripheral blood film, red cells show hypochromia, anisopoikilocytosis, target 
cells, fragmented cells and tear drop cells; white cells show leucocytosis predominantly 
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granulocytes, left shift of neutrophils with toxic granulation. The glycaemic profile was within 
normal limits. HIV screening was non-reactive.  
 
Catheter swab culture yielded Escherichia coli resistant to all tested antibiotics. Urethral swab 
culture yielded Pseudomonas aeruginosa resistant to all tested antibiotics. Sputum culture 
yielded Staphylococcus aureus resistant to all tested antibiotics. He was resuscitated and 
transferred into the Intensive care Unit. He was transfused with four pints of O negative packed 
red blood cells, his blood group being O negative. 
 
The severe weakness and fever persisted, hence the antibiotic was changed from levofloxacine 
to vancomycin, but there was no improvement. Subsequently the antibiotic was changed to 
meropenem. He then began to make gradual steady improvement and sustained clinical 




The most common complications following prostate biopsy include infection, bleeding, and 
urinary retention1,2. Infection-related complications following prostate biopsy include 
asymptomatic bacteriuria, urinary tract infection, febrile urinary tract infection, and sepsis3. Our 
patient also did not manifest urinary symptoms except for being febrile. It is highly worrisome 
the findings from recent reports of an increasing number of men requiring hospitalization as a 
result of significant infectious complications following prostate biopsy4. Although the cause of 
these recently reported trends may be multifactorial, the emerging pattern of                                     
fluoroquinolone-resistant bacteria5-7 and the lack of an evidence-based, standardized regimen 
for peri-procedural antimicrobial prophylaxis for prostate biopsy appear to be the most 
important etiologic factors responsible for these trends8.  
Although, our patient had pre-biopsy prophylaxis with a starting dose of IV Gentamycin, he was 
immediately placed on oral fluoroquinolone, ciprofloxacin post biopsy because of the extended 
biopsy experienced. With good tissue penetration and randomized trials supporting its benefit, 
most literature has supported ciprofloxacin is the choice of prophylactic agent for transrectal 
prostate biopsy9,10. Alternative attempts to cover the common organisms E. coli, K. pneumoniae, 
P. aeruginosa and Enterococcus include another fluoroquinolone, a second or third generation 
cephalosporin or Gentamycin11,12. There is no good evidence supporting the use of 
metronidazole12. 
  
However, the different bacterial isolates in our patient, with their multidrug resistance features 
highly suggest the high antibiotic consumption rate either by the patient or the local community 
of the hospital where patient presented. This is largely due to the non existence of antibiotic 
policy and guidelines in our local environment13. Also, a multi organism sepsis is the likely cause 
of severe sepsis in this patient. Most prostate biopsies are performed transrectally, and 




This report reminds us that serious complications can occur as a result of transrectal prostate 
biopsy. Further research needs to be done to evaluate the prevalence of drug resistance and to 
select an optimal prophylaxis regimen. There is also an urgent need for antibiotic audit and the 
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